Is there a need for routine testing of ICD defibrillation capacity?: Results from more than 1000 studies
Is there a need for routine testing of ICD defibrillation capacity?: Results from more than 1000 studies
复制标题
DOI：
10.1053/euhj.1999.1716
复制
发表时间：
2000-01-01
影响因子：
39.3
通讯作者：
Block, M
中科院分区：
文献类型：
--
作者：
Brunn, J;Böcker, D;Block, M
目的：术后植入式心律转复除颤器试验是有争议的植入式器官除颤功能的手术试验。本研究旨在评估心律转复除颤器很少显示功能障碍的必要性。作为植入术后除颤功能试验。方法和结果我们回顾性分析了1007例怀疑有功能障碍的患者，以及587例系统中添加了I类或III类抗心律失常药物的植入式心律转复除颤器试验的患者，556例患者。九百三十植入抗心律失常药物疗法。心律转复除颤器试验（89.4%）是常规的。71例（7%）是在改变抗心律失常药物治疗方案后进行的，6例（0.60%）是由于怀疑植入式心律转复除颤器功能障碍而进行的。在例行检查中。4个系统（0.4%）患者除颤器失败。然而。除了一个例外。试验前已观察到系统异常。在添加抗心律失常药物后，71个植入式心律转复除颤器系统中有2个（2.8%）未能除颤患者。由于疑似功能障碍，测试的六个系统中有一个未能对患者进行除颤。16次试验（1.6%）。并发症发生。结论：我们的经验表明，植入式心律转复除颤器的术后除颤功能测试很少显示功能障碍。由于检测对患者来说是不愉快的，而且并非没有并发症，因此检测可能仅限于那些怀疑有功能障碍的患者，以及那些在抗心律失常药物治疗方案中添加了I类或III类抗心律失常药物的患者。
Aims Benefits and complications of postoperative implant-Conclusions Our experience demonstrates that postoperative implantable cardioverter-defibrillator tests are controversial operative tests of the defibrillation function of implantable matters. This study sought to assess the necessity of cardioverter-defibrillators rarely reveal dysfunctions. As defibrillation function tests after implantation. testing is unpleasant for the patient and not free of complications, rests might be restricted to those patients in whomMethods and Results We retrospectively analysed 1007 a dysfunction is suspected and to those patients in whom implantable cardioverter-defibrillator tests in 587 systems class I or class III antiarrhythmic drugs have been added to and 556 patients. Nine hundred and thirty implantable the antiarrhythmic drug regimen. cardioverter-defibrillator tests (89.4%) were routinely performed. Seventy-one tests (7%) were performed after a change in the antiarrhythmic drug regimen and six tests (0.60%) because of a suspected dysfunction of the implantable cardioverter-defibrillator. during routine tests. four systems (0.4%) failed to defibrillate the patient. However. in all but one lest. abnormalities of the system had been observed before the test. After the addition of antiarrhythmic drugs, two of 71 implantable cardioverter-defibrillator systems (2.8%) failed to defibrillate the patient. One of six systems tested due to a suspected dysfunction failed to defibrillate the patient. During 16 tests (1.6%). complications occurred.Conclusions Our experience demonstrates that postoperative tests of the defibrillation function of implantable cardioverter-defibrillators rarely reveal dysfunctions. As testing is unpleasant for the patient and not free of complications, tests might be restricted to those patients in whom a dysfunction is suspected and to those patients in whom class I or class III anntiarrhytmic drugs have been added to the antiarrhythmic drug regimen.